PE20190318A1 - Composicion administrable oralmente - Google Patents
Composicion administrable oralmenteInfo
- Publication number
- PE20190318A1 PE20190318A1 PE2018001609A PE2018001609A PE20190318A1 PE 20190318 A1 PE20190318 A1 PE 20190318A1 PE 2018001609 A PE2018001609 A PE 2018001609A PE 2018001609 A PE2018001609 A PE 2018001609A PE 20190318 A1 PE20190318 A1 PE 20190318A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- orally administrable
- micellas
- refers
- combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION ADMINISTRABLE ORALMENTE QUE COMPRENDE UN AGENTE FORMADOR DE PELICULA FISIOLOGICAMENTE ACEPTABLE TAL COMO PULULANO, METIL CELULOSA, ETIL CELULOSA, CARBOXIMETIL CELULOSA SODICA, ENTRE OTROS, EN UNA CANTIDAD DEL 5 AL 80% EN PESO, COMBINADA CON UNA COMPOSICION MICELAR QUE COMPRENDE UN CANNABINOIDE TAL COMO ACIDO CANNABIDIOL (CBDA), CANNABINOL (CBN), ENTRE OTROS, EN UNA CANTIDAD DE 0.1 A 30% EN PESO DE LA COMPOSICION ENCAPSULADA EN MICELAS; DONDE LAS MICELAS SE FORMAN MEDIANTE UN PRIMER COMPUESTO FORMADOR DE MICELAS, Y OPCIONALMENTE UN SEGUNDO COMPUESTO FORMADOR DE MICELAS, EN UN SOLVENTE ACUOSO FARMACEUTICAMENTE ACEPTABLE QUE COMPRENDE UN SALICILATO DE METAL ALCALINO Y UN EDETATO FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. DICHA COMPOSICION ES EFECTIVA PARA EL SUMINISTRO DE COMPUESTOS TERAPEUTICOS GRANDES TALES COMO PROTEINAS O CANNABINOIDES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/059,444 US11166912B2 (en) | 2016-03-03 | 2016-03-03 | Orally administrable composition |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190318A1 true PE20190318A1 (es) | 2019-03-04 |
Family
ID=59722571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001609A PE20190318A1 (es) | 2016-03-03 | 2017-02-27 | Composicion administrable oralmente |
Country Status (11)
Country | Link |
---|---|
US (1) | US11166912B2 (es) |
EP (1) | EP3423037A4 (es) |
AU (1) | AU2017225927B2 (es) |
BR (1) | BR112018067586A2 (es) |
CL (1) | CL2018002474A1 (es) |
CO (1) | CO2018010549A2 (es) |
CU (1) | CU20180097A7 (es) |
IL (1) | IL261479B2 (es) |
PE (1) | PE20190318A1 (es) |
WO (1) | WO2017147691A1 (es) |
ZA (1) | ZA201805802B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11033493B2 (en) | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US20220079881A1 (en) * | 2016-03-03 | 2022-03-17 | Ctt Pharma Inc. | Orally Administrable Composition |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
EP3528784B1 (en) * | 2016-10-21 | 2023-08-02 | APIRX Pharmaceutical USA, LLC | Suppositories comprising cannabinoids |
EP3773512A4 (en) * | 2018-04-03 | 2021-12-29 | Pure Green, LLC | Tablet or composition having n-acyl ethanolamine and cannabinoid |
WO2019204630A1 (en) * | 2018-04-18 | 2019-10-24 | Leading Edge Pharms Inc. | Cbd nanoencapsulation composition and method of use |
US10751299B2 (en) * | 2018-09-04 | 2020-08-25 | Babak Ghalili | Cannabinoid and menthol compositions and methods |
US11185526B2 (en) | 2018-09-04 | 2021-11-30 | Babak Ghalili | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods |
US11602504B2 (en) | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
US10588871B1 (en) | 2019-06-28 | 2020-03-17 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
CN112569220B (zh) * | 2019-09-30 | 2023-03-07 | 云南汉盟制药有限公司 | 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物 |
GB2587621A (en) * | 2019-09-30 | 2021-04-07 | Biofilm Ltd | Oral films and a methods for the manufacture and delivery thereof |
CN111117125A (zh) * | 2019-12-30 | 2020-05-08 | 武汉轻工大学 | 一种复合抗菌膜及其制备方法 |
CN113116868B (zh) * | 2019-12-31 | 2022-08-19 | 汉义生物科技(北京)有限公司 | 四氢次大麻酚在肺动脉高压的预防和/或治疗中的应用 |
WO2021243188A1 (en) * | 2020-05-29 | 2021-12-02 | Hemp Synergistics | Powderized cannabis oil |
US11786475B2 (en) * | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
WO2022027053A1 (en) * | 2020-07-28 | 2022-02-03 | Wsmef, Llc | Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality |
WO2022122471A1 (en) | 2020-12-09 | 2022-06-16 | I+Med S. Coop. | Composition comprising sea water and cannabinoid loaded submicroparticles for pharmaceutical, nutraceutical and cosmetic applications |
US12011470B2 (en) | 2021-07-28 | 2024-06-18 | Clint Sorensen | Micelle preparations of full-spectrum hemp oil |
WO2023039587A2 (en) * | 2021-09-13 | 2023-03-16 | Arriaga Adan | Cannabinoid composition and method of using the same |
US12016401B2 (en) * | 2022-04-15 | 2024-06-25 | Air 2, LLC | Aerosol pressurized inhalation delivery device and methods for manufacture and use of the same |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117773A (en) * | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
CA2229286C (en) | 1998-02-10 | 2005-07-26 | Generex Pharmaceuticals Inc. | Mixed micellar delivery system and method of preparation |
US6350458B1 (en) * | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US6312665B1 (en) | 1998-12-21 | 2001-11-06 | Generex Pharmaceuticals Incorporated | Aerosol formulations for buccal and pulmonary application |
US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
AU4445201A (en) * | 2000-03-30 | 2001-10-08 | Generex Pharmaceuticals Inc. | Method for administering insulin to the buccal region |
YU69902A (sh) | 2000-03-31 | 2005-07-19 | Pfizer Products Inc. | Novi derivati piperazina |
US6398589B1 (en) | 2000-09-07 | 2002-06-04 | Richard A. Congelliere | Device for restricting operation of an electrical tool |
AU2002952597A0 (en) | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
CN101309668A (zh) | 2005-11-30 | 2008-11-19 | 健乐克斯医药公司 | 经口吸收的药物制剂和用药方法 |
WO2009015456A1 (en) | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
CA2624110C (en) | 2008-03-27 | 2010-11-09 | Pankaj Modi | A rapidly-dissolving orally administrable wafer formulation |
US8623401B2 (en) * | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
JP2011526888A (ja) | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
US8808734B2 (en) | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
RU2016129536A (ru) | 2013-10-31 | 2018-01-31 | Фулл Спектрум Лабораториз, Лтд. | Препараты на основе терпенов и каннабиноидов |
-
2016
- 2016-03-03 US US15/059,444 patent/US11166912B2/en active Active
-
2017
- 2017-02-27 AU AU2017225927A patent/AU2017225927B2/en not_active Ceased
- 2017-02-27 EP EP17759030.4A patent/EP3423037A4/en active Pending
- 2017-02-27 WO PCT/CA2017/050250 patent/WO2017147691A1/en active Application Filing
- 2017-02-27 CU CU2018000097A patent/CU20180097A7/es unknown
- 2017-02-27 PE PE2018001609A patent/PE20190318A1/es unknown
- 2017-02-27 IL IL261479A patent/IL261479B2/en unknown
- 2017-02-27 BR BR112018067586A patent/BR112018067586A2/pt active Search and Examination
-
2018
- 2018-08-29 ZA ZA2018/05802A patent/ZA201805802B/en unknown
- 2018-08-30 CL CL2018002474A patent/CL2018002474A1/es unknown
- 2018-10-01 CO CONC2018/0010549A patent/CO2018010549A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2018010549A2 (es) | 2018-12-14 |
CL2018002474A1 (es) | 2019-01-18 |
AU2017225927A1 (en) | 2018-10-04 |
AU2017225927B2 (en) | 2021-07-01 |
EP3423037A4 (en) | 2019-11-27 |
IL261479B1 (en) | 2023-05-01 |
WO2017147691A1 (en) | 2017-09-08 |
US11166912B2 (en) | 2021-11-09 |
EP3423037A1 (en) | 2019-01-09 |
ZA201805802B (en) | 2019-06-26 |
BR112018067586A2 (pt) | 2019-01-08 |
US20170252300A1 (en) | 2017-09-07 |
IL261479A0 (en) | 2018-10-31 |
IL261479B2 (en) | 2023-09-01 |
IL261479A (en) | 2021-03-25 |
CU20180097A7 (es) | 2019-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190318A1 (es) | Composicion administrable oralmente | |
CL2018003452A1 (es) | Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. | |
HRP20201506T1 (hr) | Uporaba kanabidiolne kiseline u liječenju epilepsije | |
BR112018011777A2 (pt) | composições de fenfluramina e métodos para o preparo das mesmas | |
AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
PE20200404A1 (es) | Composicion farmaceutica de clorhidrato de s-ketamina | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
AR078159A1 (es) | Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica. | |
PE20200383A1 (es) | Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados | |
BR112015025172A2 (pt) | composição farmacêutica | |
PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
PE20200698A1 (es) | Gel que comprende clorhexidina | |
CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
WO2012071389A3 (en) | Stable cannabinoid compositions and methods for making and storing them | |
RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
BR112014028069A2 (pt) | composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica | |
AR059927A1 (es) | Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas | |
AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
AR078785A1 (es) | Formulaciones de bazedoxifeno con antioxidantes | |
BR112017017643A2 (pt) | formulação farmacêutica tópica | |
BR112015007045A2 (pt) | composição de cuidado pessoal | |
WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
AR101136A1 (es) | Proceso para la preparación de ácidos 3-hidroxipicolínicos |